Back to Journals » Pragmatic and Observational Research » Volume 8

The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials

Authors Albertson TE, Murin S, Sutter ME, Chenoweth JA

Received 16 June 2017

Accepted for publication 15 August 2017

Published 20 September 2017 Volume 2017:8 Pages 175—181

DOI https://doi.org/10.2147/POR.S144157

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 4

Editor who approved publication: Professor David Price


Timothy E Albertson,1–3 Susan Murin,1,2 Mark E Sutter,2,3 James A Chenoweth2,3

1Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of California, Davis, Sacramento, 2Department of Medicine, Veterans Administration Northern California Healthcare System, Mather, 3Department of Emergency Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA

Abstract: The Salford Lung Study (SLS) of patients with asthma and chronic obstructive pulmonary disease (COPD) is a practical, community-based, randomized, open-label pragmatic study on the efficacy and safety of the once-daily dry powder inhaler that combines the inhaled corticosteroid fluticasone furoate (FF) with the long-acting beta2 agonist vilanterol (VI). The asthma component of the SLS is not yet reported but the COPD component, done over a 12-month period, found a statistically significant 8.4% reduction in COPD exacerbations when compared to usual care. No differences in adverse events, including serious adverse events and pneumonia, were noted. The importance of real-world findings, such as those found in the SLS COPD trial with inhaled FF/VI, is discussed in comparison to classical randomized controlled trials (RCTs) with inhaled FF/VI in COPD patients. The real-world, community-based pragmatic RCT like the SLS provides additional generalizable data with direct clinical applicability and potential usefulness in the development of practice guidelines. The results from the SLS, along with those of large and small RCTs, are supportive of the use of once-daily FF/VI in COPD maintenance therapy.

Keywords: Salford Lung Study, pragmatic randomized controlled trials, asthma, COPD, ­fluticasone furoate, FF, vilanterol, VI, COPD exacerbations

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]